Accumulation of attenuating mutations in varying proportions within a high passage very virulent plus strain of Gallid herpesvirus type 2

Virus Research

Volumn 149, Issue 2, 2010, Pages 135-142

  Spatz, Stephen J ^a  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Attenuation; DNA sequence; Gallid herpesvirus type 2; Genome; Marek's disease; Serial passage

Indexed keywords

ARGININE; INTERLEUKIN 8; ONCOPROTEIN; ONCOPROTEIN MEQ; TELOMERASE; THYMIDINE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS DNA; VIRUS LIPASE; VIRUS PROTEIN; VIRUS PROTEIN L1;

ARTICLE; BINDING SITE; CONSENSUS SEQUENCE; DNA PACKAGING; DNA REPLICATION; GENE DELETION; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENE STRUCTURE; LONG INTERNAL REPEAT; LONG TERMINAL REPEAT; MARDIVIRUS; NONHUMAN; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PATHOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SEQUENCE ANALYSIS; SHORT INTERNAL REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; STRAIN DIFFERENCE; UNIQUE LONG REGION; VIRUS ATTENUATION; VIRUS CULTURE; VIRUS GENE; VIRUS GENOME; VIRUS MUTATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; BASE SEQUENCE; CELL LINE; CHICKENS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DUCKS; FIBROBLASTS; MARDIVIRUS; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE ANALYSIS, DNA; SERIAL PASSAGE; VIRULENCE; VIRULENCE FACTORS;

AVES; GALLID HERPESVIRUS 2;

EID: 77950628594     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.01.007     Document Type: Article

References (47)

1. Calnek B.W., Fabricant J., Schat K.A., Murthy K.K. Pathogenicity of low-virulence Marek's disease viruses in normal versus immunologically compromised chickens. Avian Dis. 1977, 21(3):346-358.
2. Chen J.L., Blasco M.A., Greider C.W. Secondary structure of vertebrate telomerase RNA. Cell 2000, 100(5):503-514.
3. Chen J.L., Greider C.W. An emerging consensus for telomerase RNA structure. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(41):14683-14684.
4. Chen J.L., Opperman K.K., Greider C.W. A critical stem-loop structure in the CR4-CR5 domain of mammalian telomerase RNA. Nucleic Acids Res. 2002, 30(2):592-597.
5. Dudnikova E., Vlasov A., Norkina S., Kireev D., Witter R.L. Factors influencing the attenuation of serotype 1 Marek's disease virus by serial cell culture passage and evaluation of attenuated strains for protection and replication. Avian Dis. 2009, 53(1):63-72.
6. Endoh D. Enhancement of gene expression by Marek's disease virus homologue of the herpes simplex virus-1 ICP4. Jpn. J. Vet. Res. 1996, 44(2):136-137.
7. Fragnet L., Blasco M.A., Klapper W., Rasschaert D. The RNA subunit of telomerase is encoded by Marek's disease virus. J. Virol. 2003, 77(10):5985-5996.
8. Fragnet L., Kut E., Rasschaert D. Comparative functional study of the viral telomerase RNA based on natural mutations. J. Biol. Chem. 2005, 280(25):23502-23515.
9. Gimeno I., Witter R., Hunt H.D., Reddy S., Neumann U. Differential attenuation of the induction by Marek's disease virus of transient paralysis and persistent neurological disease: a model for pathogenesis studies. Avian Pathol. 2001, 30(4):397-409.
10. Jarosinski K., Kattenhorn L., Kaufer B., Ploegh H., Osterrieder N. A herpesvirus ubiquitin-specific protease is critical for efficient T cell lymphoma formation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(50):20025-20030.
11. Jarosinski K.W., O'Connell P.H., Schat K.A. Impact of deletions within the Bam HI-L fragment of attenuated Marek's disease virus on vIL-8 expression and the newly identified transcript of open reading frame LORF4. Virus Genes 2003, 26(3):255-269.
12. Jarosinski K.W., Osterrieder N., Nair V.K., Schat K.A. Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a. J. Virol. 2005, 79(18):11647-11659.
13. Kamil J.P., Tischer B.K., Trapp S., Nair V.K., Osterrieder N., Kung H.J. vLIP, a viral lipase homologue, is a virulence factor of Marek's disease virus. J. Virol. 2005, 79(11):6984-6996.
14. Karpathy R.C., Firth G.A., Tannock G.A. Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus. Aust. Vet. J. 2002, 80(1-2):61-66.
15. Katoh K., Kuma K., Toh H., Miyata T. MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res. 2005, 33(2):511-518.
16. Lee L.F., Wu P., Sui D., Ren D., Kamil J., Kung H.J., Witter R.L. The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(11):6091-6096.
17. Levy A.M., Izumiya Y., Brunovskis P., Xia L., Parcells M.S., Reddy S.M., Lee L., Chen H.W., Kung H.J. Characterization of the chromosomal binding sites and dimerization partners of the viral oncoprotein Meq in Marek's disease virus-transformed T cells. J. Virol. 2003, 77(23):12841-12851.
18. Lupiani B., Lee L.F., Cui X., Gimeno I., Anderson A., Morgan R.W., Silva R.F., Witter R.L., Kung H.J., Reddy S.M. Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(32):11815-11820.
19. Maotani K., Kanamori A., Ikuta K., Ueda S., Kato S., Hirai K. Amplification of a tandem direct repeat within inverted repeats of Marek's disease virus DNA during serial in vitro passage. J. Virol. 1986, 58(2):657-660.
20. Margulies M., Egholm M., Altman W.E., Attiya S., Bader J.S., Bemben L.A., Berka J., Braverman M.S., Chen Y.J., Chen Z., Dewell S.B., Du L., Fierro J.M., Gomes X.V., Godwin B.C., He W., Helgesen S., Ho C.H., Irzyk G.P., Jando S.C., Alenquer M.L., Jarvie T.P., Jirage K.B., Kim J.B., Knight J.R., Lanza J.R., Leamon J.H., Lefkowitz S.M., Lei M., Li J., Lohman K.L., Lu H., Makhijani V.B., McDade K.E., McKenna M.P., Myers E.W., Nickerson E., Nobile J.R., Plant R., Puc B.P., Ronan M.T., Roth G.T., Sarkis G.J., Simons J.F., Simpson J.W., Srinivasan M., Tartaro K.R., Tomasz A., Vogt K.A., Volkmer G.A., Wang S.H., Wang Y., Weiner M.P., Yu P., Begley R.F., Rothberg J.M. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437(7057):376-380.
21. Niikura M., Dodgson J., Cheng H. Direct evidence of host genome acquisition by the alphaherpesvirus Marek's disease virus. Arch. Virol. 2005, 151:537-549.
22. O'Hare P., Hayward G.S. Evidence for a direct role for both the 175,000- and 110,000-molecular-weight immediate-early proteins of herpes simplex virus in the transactivation of delayed-early promoters. J. Virol. 1985, 53(3):751-760.
23. O'Hare P., Hayward G.S. Comparison of upstream sequence requirements for positive and negative regulation of a herpes simplex virus immediate-early gene by three virus-encoded trans-acting factors. J. Virol. 1987, 61(1):190-199.
24. Parcells M.S., Lin S.F., Dienglewicz R.L., Majerciak V., Robinson D.R., Chen H.C., Wu Z., Dubyak G.R., Brunovskis P., Hunt H.D., Lee L.F., Kung H.J. Marek's disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV. J. Virol. 2001, 75(11):5159-5173.
25. Peng F., Bradley G., Tanaka A., Lancz G., Nonoyama M. Isolation and characterization of cDNAs from BamHI-H gene family RNAs associated with the tumorigenicity of Marek's disease virus. J. Virol. 1992, 66(12):7389-7396.
26. Peng Q., Zeng M., Bhuiyan Z.A., Ubukata E., Tanaka A., Nonoyama M., Shirazi Y. Isolation and characterization of Marek's disease virus (MDV) cDNAs mapping to the BamHI-I2, BamHI-Q2, and BamHI-L fragments of the MDV genome from lymphoblastoid cells transformed and persistently infected with MDV. Virology 1995, 213(2):590-599.
27. Rispens B.H., van Vloten H., Mastenbroek N., Maas H.J., Schat K.A. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis. 1972, 16(1):108-125.
28. Ross N., Binns M.M., Sanderson M., Schat K.A. Alterations in DNA sequence and RNA transcription of the Bam HI-H fragment accompany attenuation of oncogenic Marek's disease herpesvirus. Virus Genes 1993, 7(1):33-51.
29. Schat K.A., Hooft van Iddekinge B.J., Boerrigter H., O'Connell P.H., Koch G. Open reading frame L1 of Marek's disease herpesvirus is not essential for in vitro and in vivo virus replication and establishment of latency. J. Gen. Virol. 1998, 79(Pt 4):841-849.
30. Schumacher D., Tischer B.K., Reddy S.M., Osterrieder N. Glycoproteins E and I of Marek's disease virus serotype 1 are essential for virus growth in cultured cells. J. Virol. 2001, 75(23):11307-11318.
31. Silva R.F., Gimeno I. Oncogenic Marek's disease viruses lacking the 132 base pair repeats can still be attenuated by serial in vitro cell culture passages. Virus Genes 2007, 34(1):87-90.
32. Silva R.F., Reddy S.M., Lupiani B. Expansion of a unique region in the Marek's disease virus genome occurs concomitantly with attenuation but is not sufficient to cause attenuation. J. Virol. 2004, 78(2):733-740.
33. Silva R.F., Witter R.L. Genomic expansion of Marek's disease virus DNA is associated with serial in vitro passage. J. Virol. 1985, 54(3):690-696.
34. Spatz S.J., Petherbridge L., Zhao Y., Nair V. Comparative full-length sequence analysis of oncogenic and vaccine (Rispens) strains of Marek's disease virus. J. Gen. Virol. 2007, 88(Pt 4):1080-1096.
35. Spatz S.J., Rue C., Schumacher D., Osterrieder N. Clustering of mutations within the inverted repeat regions of a serially passaged attenuated gallid herpesvirus type 2 strain. Virus Genes 2008, 37(1):69-80.
36. Spatz S.J., Rue C.A. Sequence determination of a mildly virulent strain (CU-2) of Gallid herpesvirus type 2 using 454 pyrosequencing. Virus Genes 2008, 36:478-489.
37. Spatz S.J., Silva R.F. Polymorphisms in the repeat long regions of oncogenic and attenuated pathotypes of Marek's disease virus 1. Virus Genes 2007, 35(1):41-53.
38. Spatz S.J., Zhao Y., Petherbridge L., Smith L.P., Baigent S.J., Nair V. Comparative sequence analysis of a highly oncogenic but horizontal spread-defective clone of Marek's disease virus. Virus Genes 2007, 35(3):753-766.
39. Trapp S., Parcells M.S., Kamil J.P., Schumacher D., Tischer B.K., Kumar P.M., Nair V.K., Osterrieder N. A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis. J. Exp. Med. 2006.
40. Tulman E.R., Afonso C.L., Lu Z., Zsak L., Rock D.L., Kutish G.F. The genome of a very virulent Marek's disease virus. J. Virol. 2000, 74(17):7980-7988.
41. van Iddekinge B.J., Stenzler L., Schat K.A., Boerrigter H., Koch G. Genome analysis of Marek's disease virus strain CVI-988: effect of cell culture passage on the inverted repeat regions. Avian Dis. 1999, 43(2):182-188.
42. Volkening J.D., Spatz S.J. Purification of DNA from the cell-associated herpesvirus Marek's disease virus for 454 pyrosequencing using micrococcal nuclease digestion and polyethylene glycol precipitation. J. Virol. Methods 2009, 157(1):55-61.
43. Witter R.L. Marek's disease virus vaccines-past, present and future (chicken vs. virus-a battle of the centuries). Current Progresson Marek's Disease Research. Proceedings of the 6th International Symposium on Marek's disease 2001, American Association of Avian Pathologists, Kennett Square, PA. K.A. Schat, R.M. Morgan, M.S. Parcells, J.L. Spencer (Eds.).
44. Witter R.L. Induction of strong protection by vaccination with partially attenuated serotype 1 Marek's disease viruses. Avian Dis. 2002, 46(4):925-937.
45. Witter R.L., Kreager K.S. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease. Avian Dis. 2004, 48(4):768-782.
46. Witter R.L., Lee L.F. Polyvalent Marek's disease vaccines: safety, efficacy and protective synergism in chickens with maternal antibodies. Avian Pathol. 1984, 13(1):75-92.
47. Witter R.L., Lee L.F., Fadly A.M. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus. Avian Dis. 1995, 39(2):269-284.